Major UK project to tackle AMR closed by aid cuts
The £265 million programme – named after Alexander Fleming the British scientist who discovered penicillin – was established in 2015 in response to a landmark UK study which found resistant infections would kill 10 million people every globally year by 2050.
The fund was designed to tackle drug resistance at its source and support experts in hundreds of laboratories in developing countries that face the greatest threat from AMR.
Termed the 'silent pandemic', AMR is directly responsible for 1.27 million deaths every year as bacteria, viruses, and other pathogens evolve to evade modern medicine.
But it's not just a problem for the developing world – in England alone, 66,730 suffered from 'serious antibiotic resistant infections' in 2023.
There are an estimated 30,000 deaths in the UK every year and, for many others, it changes their lives.
Experts have repeatedly stressed that AMR does not respect borders – and often emerge in countries with less regulation surrounding antibiotic use both to treat illness and in agriculture.
'We are having to make choices that we don't want to have to make,' Baroness Chapman, the Minister of International Development, told the International Development Committee at an evidence session in parliament today.
Baroness Chapman, who became Minister after her predecessor Anneliese Dodds resigned, has become the chief hatchet woman for the aid budget.
Last month, she announced a 40 per cent cut in real terms of the UK's contribution to Gavi, the vaccine alliance which funds immunisations for half the world's children.
'We've had to make some really tough choices. But we've decided as a government that we want to invest in defence, because that's the world we are in,' she told The Telegraph at the time.
Ashley Dalton, Parliamentary Under-Secretary of State for Public Health and Prevention in the Department of Health and Social Care, said that although the funding for the Fleming Fund has ceased, the government will continue with its 'partnerships' forged under the programme.
It is currently unclear what this means.
The Telegraph has contacted the Department of Health and Social Care, who funds the Fleming Fund, for clarification.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
26 minutes ago
- The Independent
Breast cancer breakthrough as new test could revolutionise treatment
A new test for breast cancer patients has been developed which can predict whether or not their cancer is likely to return just two weeks after they start treatment. Experts said thousands of breast cancer patients could be spared unnecessary treatment as a result. The new test has been devised by scientists to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive – which accounts for around 200,000 cases of cancer each year around the globe. Writing in the journal eBioMedicine, experts said the test means that some patients will be able to 'de-escalate' their treatment while it could also help identify those who need 'more intensive therapeutic strategies'. The test, which was developed by scientists at The Institute for Cancer Research, London, correctly identifies the 6% of patients at highest risk of relapse. Researchers analysed tumour samples from 213 patients. They found that two weeks of hormone therapy changes the characteristics of some tumours, causing them to shift their subtype. The patients with the highest risk of cancer returning had a type of tumour called Luminal B that did not change after this short-term hormone therapy. Experts said these patients will require more intensive treatment. They said the findings highlight the benefit of two weeks of hormone therapy before surgery to help guide doctors' decision making. Corresponding author of the study, Dr Maggie Cheang, from The Institute of Cancer Research, London, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'
Daily Mail
26 minutes ago
- Daily Mail
New test taken two weeks after starting treatment for breast cancer can tell if the disease is likely to return
A new test taken two weeks after starting treatment for breast cancer can tell if the disease is likely to return. The breakthrough could spare thousands of patients unnecessary therapy while allowing others to receive more intensive care sooner. Researchers at The Institute of Cancer Research, London, found taking hormone drugs for a fortnight changed the characteristics of some tumours, causing them to shift their subtype. Patients with the highest risk of relapsing had a type of tumour called Luminal B that did not change after this short-term therapy. These cases, accounting for 6 per cent of the 213 patients studied, require more intensive treatment that others could avoid. Experts say the findings, published in the journal eBioMedicine, highlight the benefit of taking hormone therapy before surgery to help guide doctors' decision making. The new test works for a type of breast cancer known as oestrogen receptor positive, human epidermal growth factor receptor 2 positive, of which there are around 200,000 cases globally each year. Study author Dr Maggie Cheang, from the ICR, said: 'To deliver truly personalised care, we need to refine how we classify breast cancer, so that each patient receives the treatment most likely to benefit them. 'While current classification relies on hormone receptor and HER2 status, we know that patients within these groups can respond very differently to the same therapy. 'Our earlier research identified distinct molecular subtypes within HER2-positive, oestrogen receptor-positive breast cancer. 'In this new study, we've shown that these subtypes can shift after just two weeks of hormone therapy. 'This insight helps us identify which patients are likely to respond well and which may show early signs of treatment resistance, offering the opportunity to tailor treatment strategies sooner. 'Ultimately, our findings move us closer to more precise, patient-centred care for this overlooked breast cancer subtype.' Professor Kristian Helin, chief executive of the IRC, added: 'By decoding the underlying biology of tumours, we can tailor treatments to individual patients.' Dr Simon Vincent, chief scientific officer at charity Breast Cancer Now, which part-funded the study, said: 'These findings add to the growing evidence that genomic testing can play a powerful role in helping to predict the risk of a woman's breast cancer coming back, particularly in people with ER-positive, HER2-positive breast cancer. 'There's potential for women to benefit hugely from this research in the future, with it ensuring they avoid undergoing unnecessary treatment and leading to more personalised treatment plans, so that women receive the most effective therapy for their specific type of breast cancer.'
BBC News
26 minutes ago
- BBC News
RSV vaccine to be offered to premature babies in Northern Ireland
A vaccination programme to tackle respiratory syncytial virus (RSV) is to be extended to cover premature babies born in Northern Ireland.A long-acting injection is to be offered for eligible children from this is a common, but highly infectious, respiratory virus that affects the breathing system, particularly in young children and older infects 90% of children by the age of two and is one of the leading causes of hospitalisation in the first year of life. An RSV vaccine has been available to pregnant women in Northern Ireland since last September and is offered from 28 weeks of new programme will cover those infants born very prematurely and too early to benefit from the RSV vaccination given to their single Nirsevimab injection offers about 80% protection and replaces Palivizumab, which gives 55% protection and is administered up to five follows advice from the Joint Committee on Vaccination and Immunisation. Chief Medical Officer Sir Michael McBride said: "Vaccinations have been extremely effective in eradicating diseases and protecting children and other vulnerable groups from serious illness and death."Worryingly, we are now seeing a decline in the uptake of childhood immunisations."Vaccinations offer children the very best start in life. Quite simply, if children aren't vaccinated, they're not protected."Health Minister Mike Nesbitt said the new vaccine would strengthen winter preparedness in the health service and reduce pressures on GPs, emergency departments and hospital admissions.
